Spirulina and TIM-3/LAG-3: Next-Generation Immune Checkpoints and T Cell Exhaustion Biology

T Cell Exhaustion: A Hierarchy, Not a Cliff

Chronic antigen exposure — in persistent viral infection or the tumour microenvironment — drives T cells along a continuum from functional effector states toward a hypofunctional "exhausted" state. This progression is not a simple on/off switch. Chromatin profiling and single-cell transcriptomics have defined at least two major subsets within the exhausted pool: progenitor exhausted T cells (Tpex) and terminally exhausted T cells (Tex). Tpex cells are characterised by expression of the transcription factors TOX and TCF1 (TCF7), retain proliferative capacity and partial effector function, and express intermediate levels of PD-1 with little to no TIM-3. They are the cells that respond to anti-PD-1 checkpoint blockade. Terminal Tex cells, in contrast, are PD-1^hiTIM-3^hi, lack TCF1, have extensively remodelled (and largely inaccessible) chromatin at effector loci, express high levels of inhibitory receptors including LAG-3, TIGIT, and CD244, and do not meaningfully re-expand in response to PD-1 blockade alone. The fate decision from Tpex to Tex is enforced epigenetically by TOX-driven chromatin remodelling and is largely irreversible once completed, which is why combination checkpoint blockade targeting multiple co-inhibitory axes is of such interest.

TIM-3 (HAVCR2): Ligands, Signalling, and Biology

TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3; gene HAVCR2) is a type I transmembrane glycoprotein with an N-terminal immunoglobulin variable (IgV) domain and a mucin-like domain. Its cytoplasmic tail lacks classical ITIM motifs but contains five tyrosines (Y256, Y263, Y296, Y316, Y320 in the human protein) that engage signalling adaptors upon phosphorylation. TIM-3 engages four structurally distinct ligands. Galectin-9, a tandem-repeat galectin secreted by tumour cells and stromal cells, cross-links TIM-3 on exhausted T cells through its carbohydrate-recognition domains binding N-glycans on the TIM-3 mucin domain; this interaction drives apoptosis in Th1 cells and suppresses cytokine production. Phosphatidylserine (PtdSer), exposed on the outer leaflet of apoptotic cells and tumour-derived exosomes, binds the IgV domain of TIM-3 through a conserved metal-ion-dependent ligand binding site (MILIBS) and engages engulfment pathways. CEACAM1 (CD66a) forms a heterodimeric cis-complex with TIM-3 on the T cell surface and acts as a co-inhibitory partner; TIM-3 cannot restrain immune responses in the absence of CEACAM1. HMGB1, an alarmin released from dying cells, is sequestered by TIM-3 on dendritic cells, limiting HMGB1-mediated nucleic acid sensing by TLR9. Downstream of TIM-3 engagement, Bat3 (HLA-B-associated transcript 3) normally associates with the TIM-3 tail, holding it in a less inhibitory state; galectin-9 or CEACAM1 binding displaces Bat3, enabling recruitment of Fyn kinase to Y256/Y263 and suppression of TCR-driven Lck activity.

LAG-3 (CD223): MHC-II Binding and Co-inhibitory Mechanism

LAG-3 (lymphocyte activation gene 3; CD223) is a CD4 homologue whose ectodomain binds MHC class II molecules with 100-fold higher affinity than CD4 itself, through a loop (D1 domain) that inserts into the MHC-II peptide-binding groove. This interaction enables LAG-3 to compete with CD4 for MHC-II access at the immunological synapse, reducing the CD4-mediated amplification of TCR signalling. LAG-3 is also expressed on regulatory T cells (Tregs), where it is required for their suppressive function — LAG-3⁺Tregs signal through MHC-II on antigen-presenting cells to suppress effector responses. A second ligand, LSECtin (CLEC4G), a C-type lectin expressed on liver sinusoidal endothelial cells and tumour cells, binds LAG-3 through a carbohydrate-dependent mechanism and is thought to contribute to immune evasion in hepatocellular carcinoma. The cytoplasmic tail of LAG-3 contains a unique EP (glutamate-proline) motif and a KIEELE hexapeptide. The KIEELE motif is essential for LAG-3's inhibitory function: mutations within it abrogate signalling even when surface expression is intact. LAG-3 recruits LAP (LAG-3-associated protein) and engages a signalling axis that limits TCR-proximal ZAP-70 phosphorylation and downstream NFAT/AP-1 transcriptional output.

PD-1 vs TIM-3 vs LAG-3: Expression Kinetics, Rescue Potential, and Synergy

PD-1 (PDCD1) is the first co-inhibitory receptor upregulated upon T cell activation; its expression peaks transiently on acutely activated effector cells and is sustained on exhausted cells. PD-1 signalling proceeds through SHP-2 (PTPN11) recruitment to its ITSM motif, which dephosphorylates TCR-proximal kinases CD3-zeta and ZAP-70, and also dephosphorylates PI3K-binding CD28, collapsing the PI3K-Akt-mTOR axis. Because Tpex cells express PD-1 but not TIM-3 and retain open chromatin, PD-1 blockade can reinvigorate them. TIM-3, by contrast, marks terminally exhausted cells with closed chromatin; anti-TIM-3 alone rescues little function, but TIM-3+PD-1 combination releases a broader pool. LAG-3 is co-expressed with PD-1 on tumour-infiltrating lymphocytes (TILs) and peripheral exhausted cells at high frequency; the combination anti-LAG-3 (relatlimab) + anti-PD-1 (nivolumab) showed superior progression-free survival versus nivolumab alone in melanoma (RELATIVITY-047 trial), providing the first clinical validation of LAG-3 as a therapeutic target and of combination co-inhibitory blockade as a strategy. The mechanistic basis for the PD-1+LAG-3 synergy is that they act on partially non-overlapping signalling steps: PD-1/SHP-2 suppresses CD3-zeta phosphorylation, while LAG-3/KIEELE suppresses ZAP-70 and downstream AP-1, so blocking both releases a larger proportion of TCR signalling flux.

Where Spirulina's Immunomodulatory Biology Is Relevant

Spirulina does not, based on current evidence, directly modulate the expression of TIM-3, LAG-3, or PD-1 on T cells. No published human or animal studies have measured checkpoint receptor expression on TILs or circulating T cells following spirulina supplementation, and extrapolating from general immunomodulatory data to checkpoint biology would be mechanistically unsupported. What is established is that spirulina's bioactive constituents — primarily phycocyanobilin (PCB) and sulphated polysaccharides — engage several nodes of the immune system that are contextually relevant to exhaustion biology. First, spirulina polysaccharides and lipopolysaccharide-like components (including calcium spirulan and LPS-related cell wall structures) activate dendritic cells via TLR4 and TLR2, promoting IL-12p70 secretion. IL-12 is the canonical inducer of T-bet (TBX21) in T cells, and T-bet directly competes with TOX for chromatin occupancy at key exhaustion loci, meaning strong IL-12 signalling during T cell priming is associated with slower exhaustion kinetics. Second, spirulina activates NK cells, increasing cytotoxic granule exocytosis and IFN-gamma production. NK cells can lyse MHC-I-low tumour targets and secrete IFN-gamma, which upregulates CIITA and MHC-II on antigen-presenting cells, potentially improving DC-T cell synapse quality and the density of pMHC-II available to LAG-3. Third, PCB's inhibition of NADPH oxidase (NOX2) via the Nox2-Rac1 interface reduces reactive oxygen species in the tumour microenvironment. Oxidative stress is a driver of TOX expression and chromatin closure in exhausted T cells, so antioxidant attenuation of the microenvironmental redox burden may, in principle, slow the Tpex-to-Tex transition. Fourth, spirulina's effects on the Treg:Teffector balance — documented in murine models showing reduced FoxP3⁺ Treg frequency with polysaccharide fractions — are directly relevant because LAG-3 is a primary effector molecule of Treg suppression via MHC-II engagement. All of these observations are mechanistically plausible connections, not demonstrated outcomes in the checkpoint blockade context; they warrant controlled investigation, particularly in the setting of combination immunotherapy.

The Cancer Immunology Context: Practical Takeaways

For individuals with cancer who are receiving or considering checkpoint blockade therapy, the most important practical points are: (1) No clinical evidence supports spirulina as an adjunct to PD-1, TIM-3, or LAG-3 inhibitor therapy, and combining supplements with checkpoint blockade should always be discussed with an oncologist because immune stimulation in the wrong context can exacerbate immune-related adverse events such as colitis, hepatitis, and pneumonitis. (2) The mechanistic plausibility of spirulina's IL-12-inducing, NK-activating, and antioxidant properties being supportive of T cell priming quality is real, but "mechanistic plausibility" is not clinical efficacy. (3) Understanding the TIM-3 and LAG-3 axes helps explain why PD-1 blockade alone fails in terminally exhausted T cell contexts — combination strategies are being developed precisely because the biology is hierarchical and multi-receptor. (4) For otherwise healthy people interested in immune resilience, spirulina's established effects on IL-12, NK cells, and oxidative tone represent a scientifically coherent rationale for use, independent of the checkpoint pharmacology context, where the complexity and stakes are categorically different.